Category: EDAP TMS SASyndicate content

FDA panel votes against EDAP's ultrasound prostate cancer ablation

July 30, 2014 by Ingrid Mezo

The FDA's expert advisory panel votes that French device maker EDAP failed to demonstrate that it's novel Ablatherm prostate cancer treatment is safe and effective.

FDA panel rejects EDAP's ultrasound prostate cancer ablation

The FDA's Gastroenterology & Urology Devices panel today voted against recommending approval of EDAP's (NSDQ:EDAP) Ablatherm system for thermal ablation of the prostate gland to treat low-risk, localized prostate cancer.

Press Release: EDAP completes FDA inspection of manufacturing site

June 30, 2014 by MassDevice

Press Release: EDAP completes FDA inspection of manufacturing site

LYON, France -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP's manufacturing site with no findings nor issuance of Form 483 observations.

EDAP creeps toward FDA approval with clean inspection

June 30, 2014 by Arezu Sarvestani

FDA inspectors find no issues at EDAP's manufacturing facility, putting the company one step closer to winning premarket approval for its ultrasound-based prostate cancer treatment.

EDAP creeps toward FDA approval with clean inspection

MGH researchers gain $30 million grant to build brain implants for treating mental illness | Medtech funding for the week of May 26, 2014

May 30, 2014 by MassDevice

Here's a look at some of the top funding stories for medical device companies this week: Mass. General gets $30M DoD grant to build brain implant for mental illness; Consano raises $3.9M to connect researchers with funders; M&A: Spectranetics prepares $200M offering to fund $230M AngioScore bid; EDAP outlines road to FDA approval for prostate cancer ultrasound therapy; Samsung dives into digital health with open platforms, $50M fund.

Mass. General gets $30M DoD grant to build brain implant for mental illness

May 28, 2014 by Arezu Sarvestani

MassDevice.com On Call

EDAP outlines road to FDA approval for prostate cancer ultrasound therapy

May 29, 2014 by Arezu Sarvestani

French device maker EDAP TMS SA has a big month ahead as it pursues FDA approval for its Ablatherm-HIFU therapeutic ultrasound technology, preparing for regulatory inspections and launching a $9.3 million funding round.

EDAP outlines road to FDA approval for prostate cancer ultrasound therapy

Prostate cancer: EDAP lands FDA date for therapeutic ultrasound

May 22, 2014 by Arezu Sarvestani

EDAP TMS lands a July date with FDA advisors to review therapeutic ultrasound in treatment of localized prostate cancer.

Prostate cancer: EDAP lands FDA date for thereapeutic ultrasound

France-based EDAP TMS SA will get its day with the FDA next month, when the agency's expert advisors will review EDAP's Ablatherm-HIFU therapeutic ultrasound technology for treatment of prostate cancer.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp